Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBT (2020 - 2025)

Apellis Pharmaceuticals has reported EBT over the past 6 years, most recently at -$203.3 million for Q4 2025.

  • Quarterly results put EBT at -$203.3 million for Q4 2025, down 1420.75% from a year ago — trailing twelve months through Dec 2025 was -$120.5 million (up 30.74% YoY), and the annual figure for FY2025 was -$120.5 million, up 30.74%.
  • EBT for Q4 2025 was -$203.3 million at Apellis Pharmaceuticals, down from $216.3 million in the prior quarter.
  • Over the last five years, EBT for APLS hit a ceiling of $401.2 million in Q4 2022 and a floor of -$219.2 million in Q2 2021.
  • Median EBT over the past 5 years was -$106.9 million (2023), compared with a mean of -$60.9 million.
  • Peak annual rise in EBT hit 480.48% in 2025, while the deepest fall reached 1420.75% in 2025.
  • Apellis Pharmaceuticals' EBT stood at $283.7 million in 2021, then surged by 41.4% to $401.2 million in 2022, then tumbled by 121.72% to -$87.2 million in 2023, then soared by 84.66% to -$13.4 million in 2024, then plummeted by 1420.75% to -$203.3 million in 2025.
  • The last three reported values for EBT were -$203.3 million (Q4 2025), $216.3 million (Q3 2025), and -$41.7 million (Q2 2025) per Business Quant data.